Recognizes May 2013 as Amyotrophic Lateral Sclerosis Awareness Month and memorialize Congress to enact legislation to provide additional funding for research in order to find a treatment and cure for amyotrophic lateral sclerosis.
By designating a specific month for ALS awareness, SCR14 intends to enhance public understanding of the challenges faced by those diagnosed with the disease, as well as their families. Furthermore, it memorializes the United States Congress to take action in providing necessary funding for research. This could potentially lead to advancements in treatment options, which are critically needed, given that ALS has no known cause or cure. The resolution's emphasis on research funding may also align well with efforts to support veterans, who have a significantly higher risk of developing ALS.
Senate Concurrent Resolution No. 14 (SCR14) recognizes May 2013 as Amyotrophic Lateral Sclerosis Awareness Month. The resolution seeks not only to raise awareness about ALS, commonly known as Lou Gehrig's disease, but also advocates for increased funding for research aimed at finding a treatment and cure for this devastating condition. ALS is characterized by the degeneration of motor neurons, leading to progressive muscle weakness and atrophy while leaving mental faculties intact. The resolution underscores the urgency of research as patients typically face dire prognoses, surviving only two to five years post-diagnosis.
The sentiment surrounding SCR14 appears largely supportive, reflecting a collective desire to elevate the profile of ALS in public discourse. Legislators from both sides of the aisle likely recognize the humanitarian need to address the issues presented by ALS. However, there could be underlying tensions regarding funding allocations, as competing health issues may vie for legislative attention and resources. Overall, the resolution promotes a message of solidarity and urgency in combating a debilitating disease.
There are no significant points of contention explicitly noted in the texts related to SCR14. However, potential discussions could arise regarding how best to allocate funds for ALS research amid myriad health priorities. Debate may focus on the effectiveness of prior funding efforts and the need for a dedicated national strategy to support ALS research. SCR14 represents a public commitment by the state to advocate for greater recognition of the disease and the people it affects, but the practicalities of funding and implementation might become focal points for legislative discourse.